Praxis plans next epilepsy study after mid-stage success

27 March 2024

USA-based Praxis Precision Medicines (Nasdaq: PRAX), a biopharma translating genetic insights into therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, closed 21% up after Tuesday’s trading.

Praxis earlier provided an update on its Phase IIa proof of concept study evaluating PRAX-628 in epilepsy patients with photo paroxysmal response (PPR).

"PRAX-628 has the potential to be the first precision sodium channel modulator for focal epilepsy patients"PPR studies measure electroencephalogram signatures after intermittent photic stimulation and are used as an indicator of anti-seizure efficacy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK